New investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are demonstrating encouraging outcomes in managing obesity and diabetes non-insulin-dependent condition. Preclinical data suggest a https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/